The 2026 Intercepting Blood Cancers Workshop (IBC) will provide a unique, interactive platform for presentations on key clinical trial data and expert clinical insights for early interventions in blood cancers and how this impacts outcomes for patients; three key topic tracks will include:

• Lymphoma, chronic lymphocytic leukemia (CLL) and monoclonal B-cell lymphocytosis (MBL)
• Multiple myeloma, smoldering myeloma (SMM) and monoclonal gammopathy of unknown significance (MGUS)
• Clonal hematopoiesis of indeterminate potential (CHIP), myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and clonal cytopenia of undetermined significance (CCUS)